Fasedienol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fasedienol" in English language version.

refsWebsite

Global rank English rank

5nih.gov

4^th place

4vistagen.com

low place

4doi.org

2^nd place

3web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

2books.google.com

3^rd place

1fiercebiotech.com

low place

8,828^th place

1pharmacytimes.com

low place

1chez-alice.fr

low place

1researchgate.net

120^th place

125^th place

1espacenet.com

800^th place

676^th place

books.google.com

Rolls ET (November 2013). Emotion and Decision Making Explained. Oxford University Press. pp. 356–. ISBN 978-0-19-965989-0.
BioScan. Oryx Press. 2009.

chez-alice.fr

ggriebel.chez-alice.fr

Griebel G, Holmes A (September 2013). "50 years of hurdles and hope in anxiolytic drug discovery" (PDF). Nature Reviews. Drug Discovery. 12 (9): 667–87. doi:10.1038/nrd4075. PMC 4176700. PMID 23989795.

doi.org

Griebel G, Holmes A (September 2013). "50 years of hurdles and hope in anxiolytic drug discovery" (PDF). Nature Reviews. Drug Discovery. 12 (9): 667–87. doi:10.1038/nrd4075. PMC 4176700. PMID 23989795.
Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL (1994). "The human vomeronasal system". Psychoneuroendocrinology. 19 (5–7): 673–86. doi:10.1016/0306-4530(94)90049-3. PMID 7938363. S2CID 36129626.
Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L (June 2014). "Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder". The American Journal of Psychiatry. 171 (6): 675–82. doi:10.1176/appi.ajp.2014.12101342. PMID 24700254. S2CID 38510058.
Kaminski RM, Marini H, Ortinski PI, Vicini S, Rogawski MA (May 2006). "The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors". The Journal of Pharmacology and Experimental Therapeutics. 317 (2): 694–703. doi:10.1124/jpet.105.098319. PMID 16415088. S2CID 95393004.

espacenet.com

worldwide.espacenet.com

US patent 8722652, Louis Monti-Bloch, "Acute Treatment of Social Phobia", published 13 November 2012, assigned to Pherin Pharmaceuticals, Inc.

fiercebiotech.com

Al Idrus A (13 September 2018). "VistaGen nabs phase 3-ready social anxiety drug from Pherin". FierceBiotech. Retrieved 2019-12-19.

nih.gov

pubmed.ncbi.nlm.nih.gov

Griebel G, Holmes A (September 2013). "50 years of hurdles and hope in anxiolytic drug discovery" (PDF). Nature Reviews. Drug Discovery. 12 (9): 667–87. doi:10.1038/nrd4075. PMC 4176700. PMID 23989795.
Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL (1994). "The human vomeronasal system". Psychoneuroendocrinology. 19 (5–7): 673–86. doi:10.1016/0306-4530(94)90049-3. PMID 7938363. S2CID 36129626.
Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L (June 2014). "Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder". The American Journal of Psychiatry. 171 (6): 675–82. doi:10.1176/appi.ajp.2014.12101342. PMID 24700254. S2CID 38510058.
Kaminski RM, Marini H, Ortinski PI, Vicini S, Rogawski MA (May 2006). "The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors". The Journal of Pharmacology and Experimental Therapeutics. 317 (2): 694–703. doi:10.1124/jpet.105.098319. PMID 16415088. S2CID 95393004.

ncbi.nlm.nih.gov

Griebel G, Holmes A (September 2013). "50 years of hurdles and hope in anxiolytic drug discovery" (PDF). Nature Reviews. Drug Discovery. 12 (9): 667–87. doi:10.1038/nrd4075. PMC 4176700. PMID 23989795.

pharmacytimes.com

Murphy J (10 December 2019). "FDA Grants Fast Track Designation to PH94B for Treatment of Social Anxiety Disorder". Pharmacy Times. Retrieved 2019-12-19.

researchgate.net

Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L (June 2014). "Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder". The American Journal of Psychiatry. 171 (6): 675–82. doi:10.1176/appi.ajp.2014.12101342. PMID 24700254. S2CID 38510058.

semanticscholar.org

api.semanticscholar.org

Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL (1994). "The human vomeronasal system". Psychoneuroendocrinology. 19 (5–7): 673–86. doi:10.1016/0306-4530(94)90049-3. PMID 7938363. S2CID 36129626.
Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L (June 2014). "Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder". The American Journal of Psychiatry. 171 (6): 675–82. doi:10.1176/appi.ajp.2014.12101342. PMID 24700254. S2CID 38510058.
Kaminski RM, Marini H, Ortinski PI, Vicini S, Rogawski MA (May 2006). "The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors". The Journal of Pharmacology and Experimental Therapeutics. 317 (2): 694–703. doi:10.1124/jpet.105.098319. PMID 16415088. S2CID 95393004.

vistagen.com

"VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Archived from the original on 2019-12-19. Retrieved 2019-12-19.
"Generalized Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Archived from the original on 2019-12-19. Retrieved 2019-12-19.
"Post-traumatic Stress Disorder :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Retrieved 2019-12-19.
"Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Archived from the original on 2019-12-19. Retrieved 2019-12-19.

web.archive.org

"VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Archived from the original on 2019-12-19. Retrieved 2019-12-19.
"Generalized Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Archived from the original on 2019-12-19. Retrieved 2019-12-19.
"Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Archived from the original on 2019-12-19. Retrieved 2019-12-19.